Bal Pharma Limited

NSE BALPHARMA.NS

Bal Pharma Limited Net Income Margin for the year ending March 31, 2024: 2.18%

Bal Pharma Limited Net Income Margin is 2.18% for the year ending March 31, 2024, a 157.77% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Bal Pharma Limited Net Income Margin for the year ending March 31, 2023 was 0.85%, a -57.63% change year over year.
Bal Pharma Limited Net Income Margin for the year ending March 31, 2022 was 2.00%, a 5.42% change year over year.
Bal Pharma Limited Net Income Margin for the year ending March 31, 2021 was 1.89%, a 126.51% change year over year.
Bal Pharma Limited Net Income Margin for the year ending March 31, 2020 was -7.14%, a -524.21% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NSE: BALPHARMA.NS

Bal Pharma Limited

CEO	Mr. Shailesh Dheerajmal Siroya
IPO Date	May 8, 2006
Location	India
Headquarters	Lakshmi Narayan Complex
Employees	868
Sector	Consumers Staples
Industries Personal Care Cleaning Supplies Cosmetics Dental Care Drugstores & Retail Pharmacies Non-Alcoholic Beverages Pharmaceuticals Plastics

Description

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Key trends

Past 5 years